BioCirc Research Laboratory, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, Pennsylvania, USA.
Department of Biomedical Engineering, Kate Gleason College of Engineering, Rochester Institute of Technology, Rochester, New York, USA.
Artif Organs. 2022 Aug;46(8):1475-1490. doi: 10.1111/aor.14242. Epub 2022 Apr 14.
Mechanical circulatory support (MCS) devices, such as ventricular assist devices (VADs) and total artificial hearts (TAHs), have become a vital therapeutic option in the treatment of end-stage heart failure for adult patients. Such therapeutic options continue to be limited for pediatric patients. Clinicians initially adapted or scaled existing adult devices for pediatric patients; however, these adult devices are not designed to support the anatomical structure and varying flow capacities required for this population and are generally operated "off-design," which risks complications such as hemolysis and thrombosis. Devices designed specifically for the pediatric population which seek to address these shortcomings are now emerging and gaining FDA approval.
To analyze the competitive landscape of pediatric MCS devices, we conducted a systematic literature review. Approximately 27 devices were studied in detail: 8 were established or previously approved designs, and 19 were under development (11 VADs, 5 Fontan assist devices, and 3 TAHs).
Despite significant progress, there is still no pediatric pump technology that satisfies the unique and distinct design constraints and requirements to support pediatric patients, including the wide range of patient sizes, increased cardiovascular demand with growth, and anatomic and physiologic heterogeneity of congenital heart disease.
Forward-thinking design solutions are required to overcome these challenges and to ensure the translation of new therapeutic MCS devices for pediatric patients.
机械循环支持(MCS)设备,如心室辅助设备(VAD)和全人工心脏(TAH),已成为治疗成人终末期心力衰竭的重要治疗选择。但此类治疗选择对儿科患者仍然有限。临床医生最初为儿科患者改编或缩小了现有的成人设备;然而,这些成人设备并非专为支持该人群所需的解剖结构和不同的流量能力而设计,通常是“非设计运行”,这存在溶血和血栓形成等并发症的风险。现在正在出现专门为儿科人群设计的、旨在解决这些缺点的设备,并获得 FDA 批准。
为了分析儿科 MCS 设备的竞争格局,我们进行了系统的文献回顾。详细研究了大约 27 种设备:8 种是已建立或以前批准的设计,19 种正在开发中(11 种 VAD、5 种 Fontan 辅助设备和 3 种 TAH)。
尽管取得了重大进展,但仍然没有满足儿科患者独特和特殊设计约束和要求的儿科泵技术,包括患者体型范围广泛、生长时心血管需求增加、以及先天性心脏病的解剖和生理异质性。
需要前瞻性的设计解决方案来克服这些挑战,并确保新的治疗性 MCS 设备能够为儿科患者所用。